LINDSAY RAE BREEDLOVE TATE
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology FORT WORTH, TX NPI 1194144451
Browse related groups: Allopathic & Osteopathic Physicians|Obstetrics & Gynecology TX MIMEDX Group, Inc. All categories
General Payments — all program years on this page
$3,005.32
- Category: General Payments
- Program years: PY2018–2024
- Record count: 19
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,869.97 across 9 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,800.00 | 5 |
| Food and Beverage | $69.97 | 4 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| MIMEDX Group, Inc. | $2,800.00 | 5 |
| Astellas Pharma US Inc | $50.54 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $19.43 | 1 |
By program year
Records — PY2024 (9)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1092611378 | Boston Scientific Corporation | $19.43 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1139296346 | Astellas Pharma US Inc | $17.76 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1139311522 | Astellas Pharma US Inc | $15.92 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1139446274 | Astellas Pharma US Inc | $16.86 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1140255835 | MIMEDX Group, Inc. | $800.00 | 04/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1140255837 | MIMEDX Group, Inc. | $1,200.00 | 05/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1140255839 | MIMEDX Group, Inc. | $200.00 | 06/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1140255841 | MIMEDX Group, Inc. | $400.00 | 07/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1140255843 | MIMEDX Group, Inc. | $200.00 | 08/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.